Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data
Similarity Data To Be Presented At 2021 ARVO Meeting
Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.
You may also be interested in...
Samsung Bioepis saw sales of its anti-TNF biosimilars in Europe drop in the first quarter of this year, though the traditionally innovative Biogen continues to look to new products and geographies to build its biosimilars presence.
Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.
In an exclusive interview, Samsung Bioepis’ head of clinical research, Il Sun Hong, tells Generics Bulletin how the company managed to put itself at the head of the pack in the chase for biosimilar Eylea (aflibercept); and how the biosimilar can coexist with biosimilars to Lucentis (ranibizumab), which may debut later this year.